Glaucocalyxin A

Research use only, not for human use.

Glaucocalyxin A-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery.

Glaucocalyxin A-SBE-β-CD could be useful with a better solubility and sustained function in drug delivery. Glaucocalyxin A activates caspase-3, decreases BAD phosphorylation, and reduces the expression of X-linked inhibitor of apoptosis protein. Glaucocalyxin A inhibits Akt phosphorylation, suppresses proliferation, and promotes apoptosis in a dose-dependent manner, but not in normal glial cells. Glaucocalyxin A inhibits collagen-stimulated tyrosine phosphorylation of Syk, LAT, and phospholipase Cγ2, the signaling events in collagen receptor GPⅥ pathway. Glaucocalyxin A could potentially be developed as an antiplatelet and antithrombotic agent, can inhibit platelet p-selectin secretion and integrin activation by convulxin, is a GPVI selective ligand.

Glaucocalyxin A induces apoptosis by mitochondrial apoptotic pathway through several steps including increasing the Bax/Bcl-2 ratio, triggering the intracellular reactive oxygen species (ROS) generation, reducing mitochondrial membrane potential (MMP), and inducing cleavage of caspase-9 and caspase-3.

——

——

Angiogenesis

EGFR

Caspase-3|Akt

——

——

79498-31-0

332.44

C20H28O4

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (150.41 mM)

CC1(C2CC(C34C(C2(CCC1=O)C)CCC(C3O)C(=C)C4=O)O)C

——

(-20℃)

With Ice Pack

≥ 2 years